William E Brady
Overview
Explore the profile of William E Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Pashankar F, Hale J, Dang H, Krailo M, Brady W, Rodriguez-Galindo C, et al.
Cancer
. 2015 Oct;
122(2):230-7.
PMID: 26485622
Background: There is a debate regarding the management of ovarian immature teratomas (ITs). In adult women, postoperative chemotherapy is standard except for stage I, grade 1 disease, whereas surgery alone...
22.
Scalici J, Finan M, Black J, Harmon M, Nicolson W, Lankes H, et al.
Gynecol Oncol
. 2015 May;
138(2):441-4.
PMID: 26013697
Objective: Participation of minority populations in clinical trials is paramount to understanding and overcoming cancer racial disparities. The goal of this project is to evaluate minority participation in published GOG...
23.
Zaino R, Brady W, Todd W, Leslie K, Fischer E, Horowitz N, et al.
Int J Gynecol Pathol
. 2014 Oct;
33(6):543-53.
PMID: 25272292
Progestins have been used in the treatment of recurrent endometrial adenocarcinoma for almost 50 yr. Some endometrial carcinomas respond to hormonal therapy, but the mechanism of action remains incompletely known....
24.
Campos S, Brady W, Moxley K, OCearbhaill R, Lee P, DiSilvestro P, et al.
Gynecol Oncol
. 2014 Mar;
133(3):537-41.
PMID: 24594074
Objective: Carcinosarcomas of the female genital tract, also called malignant mixed müllerian tumors, are aggressive biphasic tumors. Second-line treatment options in the recurrent/persistent setting have yielded marginal responses. Given the...
25.
Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada S, et al.
Cancer
. 2013 Oct;
120(3):344-51.
PMID: 24166194
Background: The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree of toxicity in patients with recurrent...
26.
Alvarez E, Brady W, Walker J, Rotmensch J, Zhou X, Kendrick J, et al.
Gynecol Oncol
. 2012 Dec;
129(1):22-7.
PMID: 23262204
Objective: This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with recurrent or persistent endometrial carcinoma (EMC). Methods: Eligible...
27.
Farley J, Brady W, Vathipadiekal V, Lankes H, Coleman R, Morgan M, et al.
Lancet Oncol
. 2012 Dec;
14(2):134-40.
PMID: 23261356
Background: Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We therefore assessed the safety and activity of...
28.
Hess L, Brady W, Havrilesky L, Cohn D, Monk B, Wenzel L, et al.
Gynecol Oncol
. 2012 Nov;
128(2):175-80.
PMID: 23123576
Background: Cost-effectiveness/cost-utility analyses are increasingly needed to inform decisions about care. Algorithms have been developed using the Functional Assessment of Cancer Therapy (FACT) quality of life instrument to estimate utility...
29.
Schilder R, Brady W, Lankes H, Fiorica J, Shahin M, Zhou X, et al.
Gynecol Oncol
. 2012 Jun;
127(1):70-4.
PMID: 22710075
Objectives: Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal carcinoma (PPC). The Gynecologic Oncology...
30.
Gold M, Brady W, Lankes H, Rose P, Kelley J, De Geest K, et al.
Gynecol Oncol
. 2012 Mar;
125(3):635-9.
PMID: 22446624
Purpose: This multi-institutional phase II trial assessed the activity and tolerability of the anti-metastatic A6 peptide that binds CD44 in patients with persistent or recurrent epithelial ovarian, fallopian tube, or...